ASH 2012 home

Article

Cancer Network presents exclusive coverage from the American Society of Hematology (ASH) annual meeting. We'll bring you onsite reports as we cover the latest research, trials, scientific advances, and controversies that are changing the way hematologic malignancies are managed and treated.Check back here daily during the meeting and watch your inbox for our exciting reports from the ASH 2012 meeting.

Cancer Network presents exclusive coverage from the American Society of Hematology (ASH) annual meeting. We'll bring you onsite reports as we cover the latest research, trials, scientific advances, and controversies that are changing the way hematologic malignancies are managed and treated.

Check back here daily during the meeting and watch your inbox for our exciting reports from the ASH 2012 meeting.

Recent Videos
4 experts are featured in this series.
4 experts are featured in this series.
1 expert is featured in this series.
7 experts are featured in this series.
7 experts are featured in this series.
5 experts are featured in this series
Related Content
Throughout 2025, our podcast highlighted experts who discussed the latest conference data, newly approved drugs, and other oncologic happenings.

Oncology On the Go Wrapped: The Top 10 Podcast Episodes of 2025

Russ Conroy
December 25th 2025
Article

Throughout 2025, our podcast highlighted experts who discussed the latest conference data, newly approved drugs, and other oncologic happenings.

Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Daniel C. McFarland, DO;Michelle Riba, MD
December 22nd 2025
Podcast

Daniel C. McFarland, DO; and Michelle B. Riba, MD, spoke about distress screening and integrating psychosocial care into oncology.

Among 35 patients with ovarian cancer treated with an antibody-based combination, the overall response rate was 23%, with a clinical benefit rate of 31%.

Botensilimab/Balstilimab Exhibits Meaningful Activity in Ovarian Cancer

Roman Fabbricatore
December 24th 2025
Article

Among 35 patients with ovarian cancer treated with an antibody-based combination, the overall response rate was 23%, with a clinical benefit rate of 31%.

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia

Krina K. Patel, MD, MSc;Manali Kamdar, MD;Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
December 15th 2025
Podcast

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

Data from the phase 3 MANUEVER trial support the approval of pimicotinib for patients in China with symptomatic tenosynovial giant cell tumors.

Pimicotinib Earns Approval in China for Tenosynovial Giant Cell Tumors

Russ Conroy
December 23rd 2025
Article

Data from the phase 3 MANUEVER trial support the approval of pimicotinib for patients in China with symptomatic tenosynovial giant cell tumors.

Results from arms C and D of the phase 3 SEQUOIA trial demonstrated that zanubrutinib alone or in combination with venetoclax yields positive results in CLL/SLL subpopulations.

Zanubrutinib Therapies Yield Durable Results in High-Risk, Treatment-Naïve CLL/SLL

ONCOLOGY Staff
December 23rd 2025
Article

Results from arms C and D of the phase 3 SEQUOIA trial demonstrated that zanubrutinib alone or in combination with venetoclax yields positive results in CLL/SLL subpopulations.